Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ultrasound test could spot dangerous heart blockages faster

NCT ID NCT05694065

Diagnosis Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study is testing a new way to diagnose blocked heart arteries using an ultrasound-based method called Ultrasonic Flow Ratio (UFR). It involves 112 people with suspected heart disease. The goal is to see if UFR can accurately identify significant blockages compared to the current standard test (FFR). If it works, this could make diagnosis quicker and less invasive.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ultrasonic Flow Ratio (UFR) assessment
What this could lead to
If successful, UFR could provide a faster, less invasive way to diagnose significant coronary blockages during standard angiography.
What could go wrong
This is a small, early-stage diagnostic study (112 participants) comparing UFR to an existing reference standard (FFR). It does not test treatment outcomes, so even if accurate, it may not improve patient health directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

112 people

The number who actually took part.

Started

Feb 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with suspected ischemic heart disease who undergo coronary angiography.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject must be ≥ 18 years * Patients suspected with ischemic heart disease * ≥ 1 diseased vessel with angiographic percent diameter stenosis between 40% and 80% in a vessel ≥ 2.5mm by visual estimation * Target vessels are limited to major epicardial coronary arteries (left anterior descending artery \[LAD\], left circumflex artery \[LCX\], right coronary artery \[RCA\]) Exclusion Criteria: * Patients with previous coronary artery bypass grafting (CABG) * Myocardial infarction within 72h of coronary angiography * Allergy to the contrast agent or adenosine * Left main coronary artery stenosis ≥ 50% * Target vessel with in-stent restenosis * Target vessel with severe tortuosity or angulation * 100% occlusion of target vessel * Target vessel spasm or injury * Target vessel with severe myocardial bridge * Target vessel with severe thrombosis * Intravascular ultrasound (IVUS) pullback fails to cover the complete target lesion * Presence of false lumen at target vessel based on IVUS * A serum creatinine level \>150 umol/l, or a glomerular filtration rate \< 45 ml/kg/1.73 m\^2 * Heart failure * Ineligible for diagnostic intervention (IVUS or FFR examination)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ischemic heart disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ischemic heart disease

Contacts and locations

Locations

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.